- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03317886
Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer
21. oktober 2017 oppdatert av: Hiroki Yamaue, Wakayama Medical University
Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer During Pancreaticoduodenectomy (MAPLE-PD Trial)
The aim of this study is to evaluate the advantage of mesenteric approach during pancreaticoduodenectomy (PD) for pancreatic ductal adenocarcinoma (PDAC).
The design of this study is multicenter randomized clinical trial, comparing oncological and surgical outcomes between mesenteric approach and conventional approach during PD for PDAC.
Studieoversikt
Status
Ukjent
Intervensjon / Behandling
Detaljert beskrivelse
Mesenteric approach starts from dissection of lymph nodes around the superior mesenteric artery (SMA) and finally performs Kocher's maneuver during PD.
The aims of this approach are 1) decrease of intraoperative blood loss volume, 2) increase of R0 rate, and 3) prevention of squeezing cancer cells out into the vessels.
However, there have been no evidence of the efficacy of this procedure.
Therefore, the aim of this study is to evaluate the efficacy of mesenteric approach during PD for PDAC, by multicenter randomized clinical trial comparing oncological and surgical outcomes between mesenteric approach and conventional approach during PD for PDAC.
Studietype
Intervensjonell
Registrering (Forventet)
354
Fase
- Fase 3
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Seiko Hirono, M.D.,PhD
- Telefonnummer: +81-73-441-0613
- E-post: seiko-h@wakayama-med.ac.jp
Studiesteder
-
-
-
Fukuoka, Japan
- Kyusyu University
-
Ta kontakt med:
- Masafumi Nakamura
-
Hirakata, Japan
- Kansai Medical University
-
Ta kontakt med:
- Masanori Kon
-
Underetterforsker:
- Sohei Satoi
-
Hiroshima, Japan
- Hiroshima University
-
Ta kontakt med:
- Yoshiaki Murakami
-
Izumo, Japan
- Shimane University
-
Ta kontakt med:
- Yoshitsugu Tajima
-
Kagoshima, Japan
- Kagoshima University
-
Ta kontakt med:
- Kousei Maemura
-
Kashihara, Japan
- Nara Medical University
-
Ta kontakt med:
- Masayuki Sho
-
Kumamoto, Japan
- Kumamoto University
-
Ta kontakt med:
- Hideo Baba
-
Nagoya, Japan
- Nagoya University
-
Ta kontakt med:
- Yasuhiro Kodera
-
Underetterforsker:
- Suguru Yamada
-
Osaka, Japan
- Osaka University
-
Ta kontakt med:
- Hidetoshi Eguchi
-
Osaka, Japan
- Osaka Medical University
-
Ta kontakt med:
- Ryosuke Amano
-
Otsu, Japan
- Shiga Medical University
-
Sayama, Japan
- Kinki University
-
Ta kontakt med:
- Ippei Matsumoto
-
Tokyo, Japan
- Tokyo Medical University
-
Ta kontakt med:
- Yuichi Nagakawa
-
Toyama, Japan
- Toyama University
-
Ta kontakt med:
- Tsutomu Fujii
-
Wakayama, Japan, 641-8510
- Wakayama Medical University
-
Underetterforsker:
- Toshio Shimokawa, PhD
-
Hovedetterforsker:
- Hiroki Yamaue, M.D., PhD
-
Underetterforsker:
- Ken-ichi Okada, M.D., PhD
-
Underetterforsker:
- Manabu Kawai, M.D., PhD
-
Underetterforsker:
- Seiko Hirono, M.D., PhD
-
Underetterforsker:
- Motoki Miyazawa, M.D., PhD
-
Underetterforsker:
- Yuji Kitahata, M.D., PhD
-
Ta kontakt med:
- Hiroki Yamaue, M.D., PhD
- Telefonnummer: +81-73-441-0613
- E-post: yamaue-h@wakayama-med.ac.jp
-
Underetterforsker:
- Ryohei Kobayashi, M.D., PhD
-
Underetterforsker:
- Mariko Doi, PhD
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
20 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Patient who are scheduled to undergo pancreaticoduodenectomy for resectable or borderline resectable (only portal vein invasion) pancreatic ductal adenocarcinoma.
- Patients whose Eastern Cooperative Oncology Group performance status are 0 or 1.
- Patients who are 20 years or older.
- Patients who have adequate organ function.
- Patients who understand sufficiently the study to provide written informed consent
Exclusion Criteria:
- Patients who have severe ischemic cardiovascular disease
- Patients who have liver cirrhosis or active hepatitis
- Patients who need oxygen due to interstitial pneumonia or lung fibrosis
- Patients who receive dialysis due to chronic renal failure
- Patients who need surrounding organ resection
- Patients who need artery reconstruction
- Patients who are diagnosed as positive para-aortic lymph node metastases based on preoperative imaging
- Patients who have active multiple cancer that is thought to influence the occurrence of adverse events
- Patients who take steroid for the long period that is thought to influence the occurrence of adverse events
- Patients who undergo laparoscopic or laparoscopy-assisted pancreaticoduodenectomy
- Patients who cannot understand ths study due to psychotic disease or psychological symptoms
- Patients whose preoperative biopsy tissues are diagnosed as other pathological findings than pancreatic ductal adenocarcinoma
- Patients who underwent gastrectomy or colon/ rectum resection previously
- Patients who have severe drug allergy to iodine and gadolinium
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Aktiv komparator: mesenteric approach
mesenteric approach starts from lymph node dissection around the superior mesenteric artery and performs Kocher's maneuver finally during pancreaticoduodenectomy.
|
pancreaticoduodenectomy for pancreatic ductal adenocarcinoma
|
Aktiv komparator: conventional approach
Conventional approach starts from Kocher's maneuver and finally performs lymph node dissection around the superior mesenteric artery during pancreaticoduodenectomy.
|
pancreaticoduodenectomy for pancreatic ductal adenocarcinoma
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
overall survival
Tidsramme: up to 48 months
|
survival from surgery to death
|
up to 48 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
operative time
Tidsramme: up to 24 months
|
time for operation
|
up to 24 months
|
time for resection
Tidsramme: up to 3 months
|
time for resection
|
up to 3 months
|
intraoperative blood loss
Tidsramme: up to 3 months
|
intraoperative blood loss volume
|
up to 3 months
|
blood transfusion volume
Tidsramme: up to 3 months
|
transfusion volume required during operation
|
up to 3 months
|
grade B/C pancreatic fistula rate
Tidsramme: up to 3 months
|
grade B/C pancreatic fistula rate according to International Study Group of Pancreatic Surgery (ISGPS) definition
|
up to 3 months
|
rate of delayed gastric emptying
Tidsramme: up to 3 months
|
rate of delayed gastric emptying according to International Study Group of Pancreatic Surgery (ISGPS) definition
|
up to 3 months
|
abdominal hemorrhage rate
Tidsramme: up to 3 months
|
abdominal hemorrhage rate according to International Study Group of Pancreatic Surgery (ISGPS) definition
|
up to 3 months
|
all morbidity rate
Tidsramme: up to 3 months
|
rate of all postoperative complications
|
up to 3 months
|
mortality rate
Tidsramme: up to 3 months
|
rate of operative death
|
up to 3 months
|
diarrhea rate
Tidsramme: up to 24 months
|
rate of postoperative rate
|
up to 24 months
|
R0 rate
Tidsramme: up to 3 months
|
pathological R0 rate
|
up to 3 months
|
R1 rate
Tidsramme: up to 3 months
|
pathological R1 rate
|
up to 3 months
|
the closest length between surgical margin and cancer cell
Tidsramme: up to 3 months
|
the closest length between surgical margin and cancer cell if R0
|
up to 3 months
|
number of harvested lymph nodes
Tidsramme: up to 3 months
|
number of harvested lymph nodes
|
up to 3 months
|
number of metastatic lymph nodes
Tidsramme: up to 3 months
|
number of metastatic lymph nodes
|
up to 3 months
|
lymph node ratio
Tidsramme: up to 3 months
|
number of metastatic lymph nodes divided by number of harvested lymph nodes
|
up to 3 months
|
recurrence free survival
Tidsramme: up to 24 months
|
survival from operation date to recurrence date
|
up to 24 months
|
site of initial recurrence
Tidsramme: up to 24 months
|
site of initial recurrence
|
up to 24 months
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Forventet)
1. desember 2017
Primær fullføring (Forventet)
30. november 2021
Studiet fullført (Forventet)
30. november 2021
Datoer for studieregistrering
Først innsendt
18. oktober 2017
Først innsendt som oppfylte QC-kriteriene
18. oktober 2017
Først lagt ut (Faktiske)
23. oktober 2017
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
24. oktober 2017
Siste oppdatering sendt inn som oppfylte QC-kriteriene
21. oktober 2017
Sist bekreftet
1. oktober 2017
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- 2128
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Duktalt adenokarsinom i bukspyttkjertelen
-
Tianjin Medical University Cancer Institute and...Har ikke rekruttert ennåPDAC - Pancreatic Ductal Adenocarcinoma
-
Sun Yat-sen UniversityRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaKina
-
Azienda Ospedaliera Universitaria Integrata VeronaRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaItalia
-
Azienda Ospedaliera Universitaria Integrata VeronaRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaItalia
-
Cedars-Sinai Medical CenterRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaForente stater
-
Radboud University Medical CenterDutch Cancer SocietyRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaNederland
-
Imperial College LondonThe Leeds Teaching Hospitals NHS Trust; Sheffield Teaching Hospitals NHS... og andre samarbeidspartnereRekrutteringBukspyttkjertelkreft | PDAC - Pancreatic Ductal AdenocarcinomaStorbritannia
-
Chinese PLA General HospitalRekrutteringNeoplasmer i bukspyttkjertelen | Bukspyttkjertelkreft | Bukspyttkjertelkreft | PDAC - Pancreatic Ductal AdenocarcinomaKina
-
SOFIERekrutteringFAP | PDAC - Pancreatic Ductal AdenocarcinomaForente stater
-
British Columbia Cancer AgencyUniversity of British ColumbiaRekrutteringHyperglykemi | Bukspyttkjertelkreft | PDAC - Pancreatic Ductal AdenocarcinomaCanada
Kliniske studier på pancreaticoduodenectomy
-
Asan Medical CenterHar ikke rekruttert ennåErnæring | Pankreaticoduodenektomi | Forsinket magetømming
-
Wakayama Medical UniversityFullførtBukspyttkjertelkreft | Galleveiskreft | Pankreatitt | Duodenal kreft | Ampulær kreftJapan
-
CHIR-NetTechnical University of MunichAvsluttetAdenokarsinom i bukspyttkjertelenTyskland
-
Yonsei UniversityUkjent